UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

Benzinga Newsdesk www.benzinga.com Positive 81.7%

Neg 0% Neu 0% Pos 81.7%

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.